HOME >> BIOLOGY >> NEWS
New approach to pulmonary hypertension shows promise

Researchers at the University of Alberta have identified a "central command system" for pulmonary hypertension, a disease that currently has no cure and kills thousands each year.

"We believe this finding opens the door to a new strategy and the development of a new stream of drugs to treat this complex and lethal disease," said Dr. Evangelos Michelakis, director of the U of A pulmonary hypertension program and senior author of the study, which appears today in the Proceedings of the National Academy of Sciences.

Much like cancer, pulmonary hypertension is caused by the uncontrolled proliferation of cells. In the case of pulmonary hypertension, these cells build up in the pulmonary arteries, block blood flow and cause perpetual high-blood pressure in the lungs and, eventually, heart failure.

Pulmonary hypertension is especially dangerous because it is difficult to diagnose, Michelakis said, adding that it can appear in anyone at any age but is most commonly found in females in their 30s. The prime symptom is shortness of breath.

"The current treatments for pulmonary hypertension do not work. At best they might somewhat prolong and improve quality of life, but nothing cures itit usually kills patients within four to five years from diagnosis," said Sebastien Bonnet, a post-doctoral fellow in the U of A Department of Medicine and first author of the paper.

However, the U of A researchers believe they've made a breakthrough in their discovery of the role that nuclear-factor-of-activated-T-lymphocytes (NFAT) play in the cause of the disease. The researchers have identified NFAT as a potential controlling element of pulmonary hypertension in both human tissues and animal models.

When it is working properly, NFAT co-ordinates several cellular functions by regulating the expression of multiple genes. It is normally activated in important health-maintaining functions, such as the regulation of immune cells and t
'"/>

Contact: Ryan Smith
ryan.smith@ualberta.ca
780-492-0436
University of Alberta
2-Jul-2007


Page: 1 2 3

Related biology news :

1. Researchers use new approach to predict protein function
2. Personalized approach to ovarian stimulation achieves high ART pregnancy rates
3. New approaches to endometriosis treatment -- mouse experiments point the way
4. Reconstructing the biology of extinct species: A new approach
5. Screening approach leads to discovery of gene linked to breast cancer
6. In new statistical approach, data decide model
7. Bigelow Laboratory Scientists develop new approach to study marine microbes
8. New understanding of schizophrenia could lead to new treatment approaches
9. Cheaper, better disease treatments expected from faster approach to developing antibodies
10. New imaging approach promises insights into multiple sclerosis
11. Different approach needed to protect brains of premature infants

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New approach pulmonary hypertension shows promise

(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: